Apollon Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Apollon Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$500K	Sell	7,339 -27	-0.4%	-$1.91K	0.01%	858
2025 Q4	$560K	Sell	7,366 -1,473	-17%	-$107K	0.01%	793
2025 Q3	$542K	Hold	8,839	–	–	0.01%	796
2025 Q2	$432K	Hold	8,839	–	–	0.01%	852
2025 Q1	$450K	Hold	8,839	–	–	0.01%	793
2024 Q4	$399K	Sell	8,839 -8,839	-50%	-$378K	0.01%	834
2024 Q3	$656K	Hold	17,678	–	–	0.02%	623
2024 Q2	$541K	Hold	17,678	–	–	0.02%	647
2024 Q1	$514K	Sell	17,678 -4	-0%	-$112	0.02%	689
2023 Q4	$487K	Buy	17,682 +4	+0%	+$91	0.02%	663
2023 Q3	$396K	Hold	17,678	–	–	0.02%	608
2023 Q2	$719K	Buy	+17,678	New	+$865K	0.03%	497

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Apollon Wealth Management's PTCT Position: Q1 2026 in Review

Apollon Wealth Management reduced its PTC Therapeutics (PTCT) stake by 0.37% in Q1 2026, selling an estimated $1.91K and leaving 7,339 shares worth $500K. The position accounts for 0.01% of the portfolio, ranked #858.

Apollon Wealth Management first reported a position in PTCT in Q2 2023 and has held it in 12 quarters since. The position peaked at $719K in Q2 2023. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Apollon Wealth Management held 7,339 shares of PTC Therapeutics worth $500K as of Q1 2026.
Apollon Wealth Management sold 27 PTC Therapeutics shares in Q1 2026, an estimated $1.91K.
PTC Therapeutics made up 0.01% of Apollon Wealth Management's portfolio in Q1 2026, its #858 holding.
Apollon Wealth Management first reported a position in PTC Therapeutics in Q2 2023 and has held it in 12 quarters since.
Apollon Wealth Management's PTC Therapeutics position peaked at $719K in Q2 2023.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.